3.4.24.B12	medicine	a single injection of ADAMTS5 siRNA induces the suppression of degradation in nucleus pulposus tissues	707311	
3.4.24.B12	medicine	ADAMTS-5 is the main aggrecanase in laryngeal squamous cell carcinoma presenting a stage-related increase up to stage III (8fold higher expression compared to normal), and thereafter decreased in stage IV. ADAMTS-5 is highly expressed by carcinoma cells. Within the cancerous and their corresponding macroscopically normal laryngeal tissues, an altered distribution and organization of multiple molecular forms (latent, activated and fragmented forms) of the enzymes is found	733436	
3.4.24.B12	medicine	ADAMTS5 is a biomarker for prediction of response to Infliximab in patients with rheumatoid arthritis	709707	
3.4.24.B12	medicine	design and development for potent and selective inhibitors of ADAMTS-4 and ADAMTS-5, which may be required for chronic osteoarthritis therapy	709044	
3.4.24.B12	medicine	overexpression of full-length ADAMTS5 suppresses B16 melanoma growth in mice. The reduced tumor growth is correlated with diminished tumor angiogenesis, together with reduced tumor cell proliferation and increased tumor cell apoptosis	733058	
3.4.24.B12	medicine	potential target for treatment of osteoarthritis	652268	
3.4.24.B12	medicine	stop progression of cartilage degradation in osteoarthritis by prevention of aggrecan cleavage via inhibition of aggrecanase	696674	
3.4.24.B12	medicine	the enzyme is a diagnostic marker in azoospermia	755570	
3.4.24.B12	medicine	the first thrombospondin type 1 repeat domain of ADAMTS5, unlike the second, has anti-angiogenic activities, ADAMTS5 is therefore an anti-angiogenic peptide and may serve as a prototype for future development into anti-cancer drugs	677997	
3.4.24.B12	medicine	therapeutic target in osteoarthritis	679302